Effect of V0251 in Acute Vertigo

NCT01583738 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2014-10-30

No results posted yet for this study

Summary

Assessment of efficacy and tolerance of a new anti-dizziness drug in acute vertigo.

Conditions

  • Acute Vertigo

Interventions

DRUG

V0251

single dose

DRUG

placebo

single dose

Sponsors & Collaborators

  • Pierre Fabre Medicament

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • Czechia
  • France
  • Germany
  • Hungary
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01583738 on ClinicalTrials.gov